Birabresib
Birabresib is a small molecule inhibitor that targets the bromodomain and extra-terminal domain (BET) family of proteins. It is primarily being investigated for its potential use in the treatment of various types of cancer.
Mechanism of Action[edit]
Birabresib functions by inhibiting the activity of BET proteins, which are involved in the regulation of gene expression. BET proteins, such as BRD2, BRD3, BRD4, and BRDT, recognize acetylated lysine residues on histone tails, facilitating the transcription of genes that are crucial for cell growth and survival. By inhibiting these proteins, Birabresib disrupts the expression of oncogenes, leading to the suppression of tumor growth.
Clinical Development[edit]
Birabresib has been evaluated in several clinical trials for its efficacy and safety in treating different types of cancer, including acute myeloid leukemia (AML), multiple myeloma, and solid tumors. Early-phase clinical trials have shown promising results, with some patients experiencing partial responses or stable disease.
Side Effects[edit]
The most common side effects observed in clinical trials of Birabresib include fatigue, nausea, vomiting, and thrombocytopenia. These side effects are generally manageable with supportive care and dose adjustments.
Research and Future Directions[edit]
Ongoing research is focused on understanding the full therapeutic potential of Birabresib, including its use in combination with other anticancer agents. Studies are also being conducted to identify biomarkers that can predict response to treatment, which could help in personalizing therapy for patients.
See Also[edit]
References[edit]
External Links[edit]
-
 | This medical article is a stub. You can help WikiMD by expanding the page. |
